The medical device company has entered a distribution partnership with the advanced energy technology company Apyx Medical
Lipocube is continuing its international expansion and will enter the US market with the announcement of a new distribution partnership with Apyx Medical. The medical device company, which launched in 2019, will collaborate with Apyx’s commercial team to bring Lipocube’s human fat tissue-harnessing technology to the United States. That means it is now available in over 86 countries.
Lipocube’s unique minimal manipulation processing technique is designed to stimulate the inherent reparative capacity of adipose tissue to deliver reproducible results in regenerative medicine, aesthetics, orthopaedics, wound healing, urology, gynaecology and reconstruction. The system is also intended to be consistent, predictable, and cost-effective.
“I am very excited about Lipocube’s new distribution partnership with Apyx Medical,” commented the plastic surgeon and co-founder of Lipocube Ltd., Steve Cohen M.D. “Apyx has done an amazing job integrating their Renuvion product into plastic surgery and cosmetic practices, so collaborating with their commercial team to bring Lipocube fat grafting and repair to the US market just makes sense. This partnership will further expand both Apyx and Lipocube leadership positions in this new paradigm of natural aesthetics.”
“We are excited to be selected to bring this innovative technology to the US market,” said the executive vice president of Apyx Medical, Todd Hornsby. “We believe Lipocube is the next-generation product line for fat processing and is a great compliment to our existing product portfolio.”
Lipocube technologies include Lipocube Nano to improve skin quality; Lipocube Hybrid Mini-Concentrated NanoFat for wrinkles and facial regeneration; Lipocube Hybrid – Concentrated NanoFat for larger volume replacement, for example, breast augmentation; and Lipocube PRP for fast and efficient PRP separation.
New innovations are also in the pipeline, with research and development guided by a scientific advisory board of plastic surgeons, dermatologists, orthopaedists and gynaecologists.
“We developed Lipocube to be the most effective option for fat processing and fat grafting,” says the plastic surgeon and fellow co-founder of Lipocube Ltd., Tunc Tiryaki M.D. “This product line has the potential to revolutionise the US aesthetic market. I believe this will be an important driver for next-generation facial procedures.”
Lipocube has also recently received FDA Clearance (510K) and has over 12 active clinical trials for various applications including burn treatments, skin regeneration, scar treatments, soft tissue volume restoration, and wound treatments.
The company’s expansion into the US market is set to build upon the 100,000 procedures by over 10,000 physicians that have already been performed with Lipocube technology.
For more information, visit lipocube.us
